Nhl clinical trials

Explore recruiting nhl clinical trials.

Recruiting nhl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nhl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma

France, Netherlands, Hungary, Czechia, Germany, Spain +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Belgium, Germany, Czechia, Spain, Hungary, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma

Spain, Sweden, Italy, Belgium, Finland, France +4 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents

Norway, Germany, Finland, Sweden, Austria, Denmark +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)

Austria, Italy, Germany, France, Netherlands, Portugal +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase I/II Trial to Determine Persistence, Safety and Clinical Activity of Allogeneic CIK Cells Transduced with a Transposon CD19-chimeric Antigen Receptor (CARCIK-CD19) in Adult and Pediatric Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia

Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Nhl trials by city

Nhl in Toronto Nhl in Vancouver Nhl in Montreal Nhl in Calgary Nhl in Edmonton Nhl in Ottawa Nhl in Winnipeg Nhl in Quebec City Nhl in Hamilton Nhl in Kitchener Nhl in London Nhl in Halifax Nhl in New York Nhl in Los Angeles Nhl in Chicago Nhl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease